Praxis Precision Medicines to Present at Upcoming December Investor Conferences
Praxis Precision Medicines (NASDAQ: PRAX) has announced its participation in two major investor conferences in December 2024. The company will present at the Piper Sandler 36th Annual Healthcare Conference in New York on December 4, featuring a fireside chat at 2:00pm ET. Additionally, Praxis will participate in the Oppenheimer Movers in Rare Disease Summit on December 12, where management will join a panel discussing rare disease companies with near-term catalysts.
Both events will take place in New York, with one-on-one meeting opportunities available for interested investors. A live webcast of the Piper Sandler presentation will be accessible through the company's website, with a replay available for 90 days afterward.
Praxis Precision Medicines (NASDAQ: PRAX) ha annunciato la sua partecipazione a due importanti conferenze per investitori a dicembre 2024. L'azienda presenterà alla 36ª Conferenza Sanitaria Annuale di Piper Sandler a New York il 4 dicembre, con una chiacchierata informale alle 14:00 ora ET. Inoltre, Praxis parteciperà al Summit Oppenheimer Movers in Rare Disease il 12 dicembre, dove il management prenderà parte a un panel che discuterà delle aziende impegnate nelle malattie rare con catalizzatori a breve termine.
Entrambi gli eventi si svolgeranno a New York, con opportunità di incontri one-to-one disponibili per gli investitori interessati. Una diretta web della presentazione di Piper Sandler sarà accessibile tramite il sito web dell'azienda, con una registrazione disponibile per 90 giorni successivi.
Praxis Precision Medicines (NASDAQ: PRAX) ha anunciado su participación en dos importantes conferencias para inversores en diciembre de 2024. La compañía presentará en la 36ª Conferencia Anual de Salud de Piper Sandler en Nueva York el 4 de diciembre, con una charla de café a las 2:00 p.m. ET. Además, Praxis participará en la Cumbre Oppenheimer Movers en Enfermedades Raras el 12 de diciembre, donde la dirección se unirá a un panel que discutirá sobre las empresas de enfermedades raras con catalizadores a corto plazo.
Ambos eventos se llevarán a cabo en Nueva York, con oportunidades para reuniones uno a uno disponibles para los inversores interesados. Una transmisión web en vivo de la presentación de Piper Sandler estará accesible a través del sitio web de la empresa, con una repetición disponible durante 90 días después.
프랙시스 정밀 의약품 (NASDAQ: PRAX)은 2024년 12월에 있을 두 개의 주요 투자자 회의에 참가한다고 발표했습니다. 이 회사는 12월 4일 뉴욕에서 열리는 파이퍼 샌들러 제36회 연례 헬스케어 컨퍼런스에서 오후 2시에 대화 형식의 발표를 진행할 예정입니다. 추가로, 프랙시스는 12월 12일 오펜하이머 희귀질환 서밋에 참여하여 경영진이 단기 촉매를 가진 희귀 질환 기업에 대한 패널 토론에 참여할 것입니다.
두 행사 모두 뉴욕에서 열리며, 관심 있는 투자자를 위한 일대일 미팅 기회가 제공됩니다. 파이퍼 샌들러 발표의 실시간 웹캐스트는 회사 웹사이트를 통해 접근 가능하며, 이후 90일간 재생할 수 있습니다.
Praxis Precision Medicines (NASDAQ: PRAX) a annoncé sa participation à deux grandes conférences pour investisseurs en décembre 2024. L'entreprise présentera lors de la 36e Conférence Annuelle sur la Santé de Piper Sandler à New York le 4 décembre, avec une discussion informelle à 14h00 ET. De plus, Praxis participera au Sommet Oppenheimer Movers sur les Maladies Rares le 12 décembre, où la direction rejoindra un panel discutant des entreprises de maladies rares disposant de catalyseurs à court terme.
Les deux événements auront lieu à New York, avec des opportunités de réunions individuelles pour les investisseurs intéressés. Un webcast en direct de la présentation de Piper Sandler sera accessible via le site Web de l'entreprise, avec une rediffusion disponible pendant 90 jours après.
Praxis Precision Medicines (NASDAQ: PRAX) hat die Teilnahme an zwei wichtigen Investorenkonferenzen im Dezember 2024 angekündigt. Das Unternehmen wird am 4. Dezember auf der 36. jährlichen Gesundheitskonferenz von Piper Sandler in New York präsentieren, einschließlich eines Fireside-Chats um 14:00 Uhr ET. Darüber hinaus wird Praxis am Oppenheimer Movers in Rare Disease Summit am 12. Dezember teilnehmen, bei dem das Management an einem Panel über Unternehmen im Bereich seltener Krankheiten mit kurzfristigen Katalysatoren teilnehmen wird.
Beide Veranstaltungen finden in New York statt, und interessierten Investoren werden One-on-One-Gesprächsmöglichkeiten angeboten. Ein Live-Stream der Präsentation von Piper Sandler wird über die Unternehmenswebsite zugänglich sein, mit einer Wiederholung, die 90 Tage danach verfügbar ist.
- None.
- None.
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences in December 2024.
- Praxis management will be participating in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference, taking place in New York, NY at the Lotte New York Palace Hotel on December 4, 2024 at 2:00pm ET. A live webcast of the event will be available through this link.
- Praxis management will also be participating in a panel titled “Elevator Pitches from Rare Disease Companies with Key Near-term, Potentially Stock-moving Catalysts” at the Oppenheimer Movers in Rare Disease Summit, taking place in New York, NY at the Westin Grand Central Hotel on December 12, 2024 at 2:00pm ET.
The Company will be available for one-on-one meetings during these conferences. Interested investors should contact their respective Piper Sandler and/or Oppenheimer representatives to request meetings.
The Piper Sandler live webcast will also be available through the “Upcoming & Recent Events” page of the Investors + Media section of the company’s website at www.praxismedicines.com. Following the event, a replay will be posted, when available, to Praxis’ website on the “Events and Presentations” page under the investor section of the website for 90 days.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
FAQ
When is Praxis Precision Medicines (PRAX) presenting at the Piper Sandler Healthcare Conference in December 2024?
What panel is PRAX participating in at the Oppenheimer Rare Disease Summit?
How long will the Piper Sandler conference webcast replay be available on PRAX's website?
Where can investors access the live webcast of PRAX's Piper Sandler presentation?
